Home
    • Plans Blog Contact
    Praxis Precision Medicines Inc logo

    Praxis Precision Medicines Inc

    PRAX
    Last price US$324.96
    Market cap US$8.9b
    12M price change 460.23%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Praxis Precision Medicines Inc Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts. Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Praxis Precision Medicines Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Net loss was -$92.6M. R&D expense was $78M.

    Net loss -$92.6M reported
    R&D expense $78M reported
    G&A expense $27.9M reported
    Cash $1.4B reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    we expect topline results from the POWER1 study of vormatrigine in focal epilepsy this quarter, followed by the EMERALD readout in broad DEEs in the fourth quarter.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 SEC filing 8-K Feb 19, 2026 Earnings material Earnings release Feb 19, 2026 SEC filing 10-K Feb 19, 2026 SEC filing 8-K Jan 06, 2026 SEC filing 10-Q Nov 05, 2025 SEC filing 8-K Nov 05, 2025 Earnings release Earnings release Nov 05, 2025 Earnings release Earnings release Aug 04, 2025 SEC filing 8-K Aug 04, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    Praxis Precision Medicines Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score 0.86/5
    Praxis Precision Medicines Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Praxis Preci... PRAX US$8.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.39/5
    Praxis Precision Medicines Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Praxis Preci... PRAX US$8.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 3.53/5
    Praxis Precision Medicines Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Praxis Preci... PRAX US$8.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Praxis Precision Medicines Inc logo

    Praxis Precision Medicines Inc

    US$324.96

    US$8.9b

    3.38%

    460.23%